Thursday, 6 April 2017


Constituent Laboratories of CSIR, namely CSIR-Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP) and CSIR-National Botanical Research Institute (CSIR-NBRI) have jointly developed a herbal formulation named NBRMAP-DB effective against diabetes. The formulation was licensed to M/s. AIMIL Pharmaceutical Pvt. Ltd., New Delhi for manufacturing the drug and marketing the same with the brand name of BGR-34. 

The formulation was evaluated on small animal model and found effective against chemical induced type-II Diabetes mellitus. M/s. AIMIL Pharmaceutical Pvt. Ltd., New Delhi had conducted the clinical trial at Agarwal Dharmarth Hospital, New Delhi and started marketing the drug with the brand name of BGR-34. Further, more detailed studies on human subjects are being conducted at Banaras Hindu University (BHU), Varanasi. 

This information was given by Minister of State for Science & Technology and Earth Sciences Shri Y.S.Chowdary in written reply to a question in Lok Sabha.


No comments:

Shri J P Nadda addresses Global Digital Health Partnership Symposium at Australia

Digital health has great potential towards reducing inequity in provisioning and distribution of healthcare resources and services: J P Na...